Gastrointestinal - Refresher 2021
Data is rapidly emerging in the treatment of locally advanced GI cancers. Issues regarding optimal radiation dose, use of radiation, use of immunotherapy and sequence have all been evaluated in phase III trial recently and have direct relevance to practice now. In this part of the course the presenters evaluate: Esophageal cancer- role of adjuvant immunotherapy, dose escalation in inoperable cancers, Pancreatic cancer- the role of preoperative radiation in borderline resectable pancreatic cancer, Rectal cancer- Total neoadjuvant therapy and non-operative management.
This part of the course outlines the current standard of care options and new data regarding the treatment of lower gastrointestinal malignancies. First it is discussed the treatment of locally advanced rectal cancer focusing on the role of radiation in the multidisciplinary treatment of this disease. Data from randomized trials presented at ASCO 2020 will be highlighted as well the ASTRO clinical practice guidelines for rectal cancer published in January/February 2021. Special topics of clinical interest will be discussed including selective omission of radiation therapy for low risk patients and non-operative management for patients with a complete clinical response after radiation. Finally discussed is the role of chemoradiation in the definitive treatment of anal squamous cell carcinoma as well as the current cooperative group trials in this space.
This activity is available from April 19, 2021, through 11:59 p.m. Eastern time on April 18, 2024.
This activity was originally recorded at ASTRO’s virtual 2021 ASTRO Annual Refresher Course, March 19-21, 2021.
The meeting is designed to meet the interests of practicing radiation oncologists, radiation oncology residents, medical and clinical physicists, nurses and all other health professionals involved in the field of radiation oncology.
Upon completion of this activity, participants should be able to do the following:
- Recognize appropriate radiation dose recommendations for non-operative management of esophageal cancer.
- Outline the data and limitations of studies evaluating neoadjuvant radiation for borderline resectable pancreatic cancer.
- Discuss the data supporting total neoadjuvant therapy for rectal cancer, and its relevance to non-operative management.
- Discuss and implement appropriate radiation options for a patient with locally advanced rectal adenocarcinoma.
- Discuss controversial topics such as omission of surgery and omission of radiation for patients with locally advanced rectal adenocarcinoma.
- Outline standard of care chemoradiation for patients with anal squamous cell carcinoma.
Theodore Hong, MD is employed by Massachusetts General Hospital and has no financial relationships with a commercial interest.
Emma Holiday, MD is employed by MD Anderson Cancer Center and has no financial relationships with a commercial interest.
All relevant relationships have been mitigated.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.
ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification.
- 1.50 Certificate of AttendanceThis activity was designated for 1.50 AMA PRA Category 1 Credit™.
- 1.50 SA-CME
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing medical education for physicians.
The American Society for Radiation Oncology (ASTRO) designates this for a maximum of 1.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity meets the American Board of Radiology's criteria for a self-assessment activity in the ABR's Maintenance of Certification program. Participation in this course in combination with the successful completion of the corresponding assessment and course evaluation adheres to the guidelines established by the ABR for 1.50 self-assessment credits.
ASTRO members must log in to the ASTRO website to view and receive the discounted member rate.
- Nonmember: $105
- Member: $55
No refunds, extensions, or substitutions will be made for participants, including those who for any reason, have not completed the course by the end of the qualification date. The qualification date for each course is listed in the course catalog on the ASTRO website under availability.
Participants using ASTRO's online courses to satisfy the requirement of a Maintenance of Certification (MOC) program should verify the number, type and availability dates of any course before making a purchase. No refunds, extensions, or substitutions will be made for participants who have purchased courses that do not align with their MOC requirement.
The course and its materials will only be available on the ASTRO website for that 3 year period regardless of purchase date. At the expiration of the qualification, participants will no longer have access to the course or its materials. ASTRO reserves the right to remove a course before the end of its qualification period.
One of the two latest versions of Google Chrome, Mozilla Firefox, Internet Explorer or Safari.